Research has examined the real-world outcomes of immunotherapy in patients with advanced non-small cell lung cancer (nsclc) who also have comorbidities. The study's findings are being reported, although the specifics of the outcomes are not detailed in the available information. The research appears to focus on the effectiveness of immunotherapy in this particular patient population.